DUBLIN, March 14, 2017 /PRNewswire/ -- Results of a
recent survey commissioned by Allergan plc to better understand the
personal impact of submental fullness as well as how others
perceive individuals with submental fullness were revealed at the
American Academy of Dermatology (AAD) Meeting in Orlando, FL. 1,996 men and women in the U.S.
between the ages of 18 and 65 were surveyed to better understand
how having a double chin plays a role in self-perception and
alternatively, how those with submental fullness are viewed by
others.1
Experience the interactive Multimedia News Release here:
https://www.multivu.com/players/English/8061651-allergan-kybella-double-chin-survey/
Results of the survey revealed:
Impact of Submental Fullness on Self-Perception, Behavior and
Social Perceptions
- 47% of respondents reported being bothered by the appearance of
the area underneath their chin. 49% said the area under their chins
negatively impacts their appearance.1
- Nearly half (45%) of respondents felt people noticed the area
under their chin.1
- 55% of female respondents (n=1,025) reported being bothered by
the area under their chin, compared to 40% (n=971) of male
respondents.1
- Survey respondents reported altering their behavior to address
their double chin. For example:
- 35% shy away from photos1
- 35% avoid video chats and conference
calls(n=488)1
- 29% of men have grown a beard to hide the area under their chin
(younger men were more likely to do this than their older peers)
(n=971)1
- Upon evaluation of photographs of individuals with varying
levels of submental fullness…
- 78% of respondents admitted they are more likely to notice a
double chin on a woman than a man.1
"We understand that submental fullness is a common
concern,4" says David
Moatazedi, Senior Vice-President of Facial Aesthetics at
Allergan. "It was important for us to dig deeper to better
understand the substantial impact that submental fullness may have
on patients' self-perception and behavior, as well as the
perception others may have of individuals with submental fullness.
Gaining a better understanding of how having a double chin plays a
role in self-perception and alternatively, how those with submental
fullness are viewed by others will help physicians in their daily
interactions with these patients."
"The results of this survey mimic what I hear from patients on a
daily basis – they are bothered by submental fullness and are
looking to address the problem. In many cases, the submental
fullness is genetic and resistant to diet or
exercise,2,3" says Dr. Shannon
Humphrey, Board-Certified Dermatologist and Co-Author of
this survey. "These findings will help physicians to better
understand the impact a double chin has on our patients so we can
address this issue and provide them with effective treatment
options."
Allergan is the maker of KYBELLA® (deoxycholic acid)
injection 10 mg/mL, the only FDA-approved injectable treatment for
adults that destroys fat cells in the treatment area under the chin
to improve a patient's profile – whether they have a moderate
amount of chin fullness or a bit more – with no
surgery.5 The active ingredient in KYBELLA®
is a non-human, non-animal formulation of deoxycholic acid.
Deoxycholic acid is a naturally occurring molecule in the body that
aids in the breakdown and absorption of dietary fat.6
When injected into the fat in the treatment area beneath the chin,
KYBELLA® physically destroys fat cells, which makes them
unable to accumulate or store fat. 5,6
In clinical studies, 88% of patients received more than one
KYBELLA® treatment,7,8 with 59% of patients
receiving six KYBELLA® treatments. Everyone has a
different level of submental fat and a licensed and trained
physician will be able to determine the number of
KYBELLA® treatments each patient will need. Multiple
injections are given under the chin per treatment and up to 6
treatments can be administered, spaced at least 1 month apart. With
KYBELLA®, once the desired result is achieved,
retreatment is not expected.5 For more information about
KYBELLA® or to find a doctor, please visit
www.mykybella.com.
KYBELLA® Indication and Important Safety
Information
What is KYBELLA®?
KYBELLA® is a
prescription medicine used in adults to improve the appearance and
profile of moderate to severe fat below the chin (submental fat),
also called "double chin."
It is not known if KYBELLA® is safe and effective for
use outside of the submental area or in children under the age of
18.
Who should not receive KYBELLA®?
You should
not receive KYBELLA® if you have an infection in the
treatment area.
Before receiving KYBELLA®, tell your healthcare
provider about all of your medical conditions, including if
you: Have had or plan to have surgery on your face, neck, or
chin; have had cosmetic treatments on your face, neck, or chin;
have had or have medical conditions in or near the neck area; have
had or have trouble swallowing; have bleeding problems; are
pregnant or plan to become pregnant (it is not known if
KYBELLA® will harm your unborn baby); are breastfeeding
or plan to breastfeed (it is not known if KYBELLA®
passes into your breast milk; talk to your healthcare provider
about the best way to feed your baby if you receive
KYBELLA®).
Tell your healthcare provider about all the medicines you
take, including prescription and over-the counter medicines,
vitamins, and herbal supplements. Especially tell your healthcare
provider if you take a medicine that prevents the clotting of your
blood (antiplatelet or anticoagulant medicine).
What are the possible side effects of
KYBELLA®?
KYBELLA® can cause
serious side effects, including nerve injury in the jaw
(which can cause an uneven smile or facial muscle weakness), or
trouble swallowing.
The most common side effects of KYBELLA®
include: swelling, bruising, pain, numbness, redness, and areas
of hardness in the treatment area.
These are not all of the possible side effects of
KYBELLA®. Call your healthcare provider for medical
advice about side effects.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.fda.gov/safety/MedWatch or
call 1-800-FDA-1088.
Please talk to your healthcare provider or visit
www.mykybella.com for full Prescribing Information.
© 2017 Allergan. All rights reserved. All trademarks
are the property of their respective owners.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global
pharmaceutical company and a leader in a new industry model –
Growth Pharma. Allergan is focused on developing, manufacturing and
commercializing branded pharmaceuticals, devices and biologic
products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class
products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women's health,
urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the Company's
R&D model, which defines our approach to identifying and
developing game-changing ideas and innovation for better patient
care. This approach has led to Allergan building one of the
broadest development pipelines in the pharmaceutical industry with
70+ mid-to-late stage pipeline programs in development.
Our Company's success is powered by our more than 16,000 global
colleagues' commitment to being Bold for Life. Together, we
build bridges, power ideas, act fast and drive results for our
customers and patients around the world by always doing what is
right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives every day.
For more information, visit Allergan's website at
www.Allergan.com.
Allergan Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective of existing trends and
information as of the date of this release. Except as expressly
required by law, Allergan disclaims any intent or obligation to
update these forward-looking statements. Actual results may differ
materially from Allergan's current expectations depending upon a
number of factors affecting Allergan's business. These factors
include, among others, the difficulty of predicting the timing or
outcome of FDA approvals or actions, if any; the impact of
competitive products and pricing; market acceptance of and
continued demand for Allergan's products; difficulties or delays in
manufacturing; and other risks and uncertainties detailed in
Allergan's periodic public filings with the Securities and Exchange
Commission, including but not limited to Allergan's Annual Report
on Form 10-K for the year ended December 31,
2016. Except as expressly required by law, Allergan
disclaims any intent or obligation to update these forward-looking
statements.
References:
1. Allergan, Data on File, Submental Fullness Survey,
April 2016.
2. Defatta, Robert, "Liposuction of the Face and Neck",
2007.
3. Schlessinger, Joel, "Perceptions and Practices in
Submental Fat Treatment: A Survey of Physicians and Patients",
SkinMed, Jan/Feb 2013.
4. American Society for Dermatologic Surgery 2015
Consumer Survey on Cosmetic Dermatologic Procedures, 2015. "How
Bothered Are You By Excess Fat Under The Chin/Neck?"
5. KYBELLA® Prescribing Information,
2015.
6. Thuangtong R, Bentow J, Knopp K, Mahmood N, David N,
Kolodney M. Tissue-Selective Effects of Injected Deoxycholate.
American Society for Dermatologic Surgery, Inc. 2010;
36(6):899-908.
7. Data On File, ATX-101-11-22 Clinical Study
Report.
8. Data On File, ATX-101-11-23 Clinical Study
Report.
CONTACTS:
Investors:
Karina
Calzadilla
(862) 261-7328
Media:
Mark Marmur
(862) 261-7558
Ember Garrett
(714) 246-3525
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/new-survey-reveals-impact-of-double-chin-on-self-perception-and-behavior-300422717.html
SOURCE Allergan plc